Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer

Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer

<b>Background:</b> The management of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved significantly in recent years due to the introduction of androgen receptor-targeted agents (ARTAs). When used alongside androgen deprivation therapy (ADT), these treatments have shown im...

Full description

Saved in:
Bibliographic Details
Main Authors: Juan A. Encarnación Navarro, Virginia Morillo Macías, María Borrás Calbo, Isabel De la Fuente Muñoz, Antonio Lozano Martínez, Vicente García Martínez, Luis Fernández Fornos, Miriam Guijarro Roche, Osamah Amr Rey, Raquel García Gómez
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Current Oncology
Subjects:
prostate cancer
apalutamide
PSA decline
ultralow PSA
Online Access:https://www.mdpi.com/1718-7729/32/3/119
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/3/119

Similar Items